23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type <i>Streptococcus pneumoniae</i>

Benzer Materyaller

• Comment on Chandler et al. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type <i>Streptococcus pneumoniae</i>. <i>Microorganisms</i> 2022, <i>10</i>, 560
  Yazar:: Nicole Cossrow, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-10-01)
• Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan
  Yazar:: Ching-Fen Shen, ve diğerleri
  Baskı/Yayın Bilgisi: (2021-09-01)
• Immunological and Epidemiological Aspects of the Immunogenicity of Streptococcus Pneumoniae Serotype 3 Capsular Polysaccharide in Pneumococcal Vaccines
  Yazar:: A. E. Zaitsev, ve diğerleri
  Baskı/Yayın Bilgisi: (2020-04-01)
• The potential role of pneumococcal conjugate vaccine in reducing acute respiratory inflammation in community-acquired pneumococcal pneumonia
  Yazar:: Ching-Fen Shen, ve diğerleri
  Baskı/Yayın Bilgisi: (2020-08-01)
• Vaccination in Adults with 23 valent Pneumococcal Polysaccharide Vaccine –ABC: Awareness, Benefits and Clinical Aspects
  Yazar:: Salil Bendre, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-02-01)